"Oncolytic Viruses" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY.
| Descriptor ID |
D050504
|
| MeSH Number(s) |
B04.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Viruses".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Viruses".
This graph shows the total number of publications written about "Oncolytic Viruses" by people in this website by year, and whether "Oncolytic Viruses" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Viruses" by people in Profiles.
-
Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Front Immunol. 2023; 14:1279387.
-
Romano G, Marino IR. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview. Drugs Today (Barc). 2019 Feb; 55(2):117-130.
-
Hingorani P, Sampson V, Lettieri C, Kolb EA. Oncolytic viruses for potential osteosarcoma therapy. Adv Exp Med Biol. 2014; 804:259-83.
-
Lettieri CK, Hingorani P, Kolb EA. Progress of oncolytic viruses in sarcomas. Expert Rev Anticancer Ther. 2012 Feb; 12(2):229-42.
-
Veerapong J, Bickenbach KA, Shao MY, Smith KD, Posner MC, Roizman B, Weichselbaum RR. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007 Sep 01; 67(17):8301-6.